Urolithiasis associated with topiramate
| Autor: | Scott Eggener, Samuel C. Kim, Herbert M. User, Joseph Pazona, Robert B. Nadler |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: | |
| Zdroj: | International Brazilian Journal of Urology, Vol 30, Iss 1, Pp 29-31 (2004) |
| Druh dokumentu: | article |
| ISSN: | 1677-5538 1677-6119 |
| DOI: | 10.1590/S1677-55382004000100006 |
| Popis: | OBJECTIVE: Topiramate is a sulfamate-substituted monosaccharide anticonvulsant used as adjunctive therapy for intractable refractory seizures. It is report a case of topiramate-induced urolithiasis. CASE REPORT: A 35-year-old man presented with acute, right-sided, colicky flank pain. He denied hematuria or dysuria. He was in use of phenytoin, risperidone, phenobarbital, and topiramate. The total daily dose of topiramate was 375 mg. A CT scan showed a 7 x 1 mm curvilinear density at the right ureterovesical junction with proximal hydrouretronephrosis. He was managed with rigid ureteroscopic stone extraction and the calculus metabolic analysis revealed the stone was composed of carbonate apatite (70%), calcium oxalate dihydrate (20%), and calcium oxalate monohydrate (10%). COMMENTS: The present case typifies many features of topiramate-induced urolithiasis. Those who care for patients with urinary stone disease should be aware of this association. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|